Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition

Clinical Science

Volumn 127, Issue 7, 2014, Pages 463-474

  Khan, Md Abdul Hye ^a   Pavlov, Tengis S ^a   Christain, Sarah V ^a   Neckář, Jan ^a,b   Staruschenko, Alexander ^a   Gauthier, Kathryn M ^a   Capdevila, Jorge H ^c   Falck, John R ^d   Campbell, William B ^a   Imig, John D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Cyp2c44 knockout mouse; Epithelial sodium channel (ENaC channel); Epoxyeicosatrienoic acid analogue; Hypertension

Indexed keywords

ANGIOTENSIN II; ASPARTIC ACID; CYTOCHROME P450 2C; DRINKING WATER; EPITHELIAL SODIUM CHANNEL; EPOXYICOSATRIENOIC ACID; HETEROCYCLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CATTLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DILATATION; DRUG SYNTHESIS; HYPERTENSION; KIDNEY COLLECTING TUBULE; KIDNEY TUBULE CELL; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASODILATATION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HEMODYNAMICS; HYPERTENSION; MALE; MICE; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; SODIUM CHANNEL BLOCKERS; VASODILATION;

EID: 84903999535     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130479     Document Type: Article

References (51)

1. Fleming, I. (2007) Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat. 82, 60-67 CrossRef PubMed
2. Fleming, I. (2008) Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc. Med. 18, 20-25 CrossRef PubMed
3. Imig, J. D. (2012) Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 92, 101-130 CrossRef PubMed
4. Zeldin, D. C. (2001) Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 276, 36059-36062 CrossRef PubMed
5. Roman, R. J. (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-185 PubMed
6. Capdevila, J. H., Pidkovka, N., Mei, S., Gong, Y., Falck, J. R., Imig, J. D., Harris, R. C. and Wang, W. (2014) The cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. J. Biol. Chem. 289, 4377-4386 CrossRef PubMed
7. Imig, J. D. (2010) Targeting epoxides for organ damage in hypertension. J. Cardiovasc. Pharmacol. 56, 329-335 CrossRef PubMed
8. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C. and Hammock, B. D. (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690-694 CrossRef PubMed
9. Imig, J. D., Zhao, X., Zaharis, C. Z., Olearczyk, J. J., Pollock, D. M., Newman, J. W., Kim, I. H., Watanabe, T. and Hammock, B. D. (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46, 975-981 CrossRef PubMed
10. Zhao, X., Yamamoto, T., Newman, J. W., Kim, I. H., Watanabe, T., Hammock, B. D., Stewart, J., Pollock, J. S., Pollock, D. M. and Imig, J. D. (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15, 1244-1253 PubMed
11. Jung, O., Brandes, R. P., Kim, I. H., Schweda, F., Schmidt, R., Hammock, B. D., Busse, R. and Fleming, I. (2005) Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45, 759-765 CrossRef PubMed
12. Loch, D., Hoey, A., Morisseau, C., Hammock, B. D. and Brown, L. (2007) Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. 47, 87-98 CrossRef PubMed
13. Manhiani, M., Quigley, J. E., Knight, S. F., Tasoobshirazi, S., Moore, T., Brands, M. W., Hammock, B. D. and Imig, J. D. (2009) Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am. J. Physiol. Renal Physiol. 297, F740-F748 CrossRef PubMed
14. Falck, J. R., Krishna, U. M., Reddy, Y. K., Kumar, P. S., Reddy, K. M., Hittner, S. B., Deeter, C., Sharma, K. K., Gauthier, K. M. and Campbell, W. B. (2003) Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am. J. Physiol. Heart Circ. Physiol. 284, H337-H349 PubMed
15. Falck, J. R., Kodela, R., Manne, R., Atcha, K. R., Puli, N., Dubasi, N., Manthati, V. L., Capdevila, J. H., Yi, X. Y., Goldman, D. H. et al. (2009) 14,15-epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J. Med. Chem. 52, 5069-5075 CrossRef PubMed
16. Yang, W., Holmes, B. B., Gopal, V. R., Kishore, R. V., Sangras, B., Yi, X. Y., Falck, J. R. and Campbell, W. B. (2007) Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J. Pharmacol. Exp. Ther. 321, 1023-1031 CrossRef PubMed
17. Falck, J. R., Reddy, L. M., Reddy, Y. K., Bondlela, M., Krishna, U. M., Ji, Y., Sun, J. and Liao, J. K. (2003b) 11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg. Med. Chem. Lett. 13, 4011-4014 CrossRef
18. Gauthier, K. M., Falck, J. R., Reddy, L. M. and Campbell, W. B. (2004) 14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol. Res. 49, 515-524 CrossRef PubMed
19. Imig, J. D., Inscho, E. W., Deichmann, P. C., Reddy, K. M. and Falck, J. R. (1999) Afferent arteriolar vasodilation to the sulfonimide analog of 11,12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension 33, 408-413 CrossRef PubMed
20. Dimitropoulou, C., West, L., Field, M. B., White, R. E., Reddy, L. M., Falck, J. R. and Imig, J. D. (2007) Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins Other Lipid Mediat. 83, 50-61 CrossRef PubMed
21. Imig, J. D., Elmarakby, A., Nithipatikom, K., Wei, S., Capdevila, J. H., Tuniki, V. R., Sangras, B., Anjaiah, S., Manthati, V. L., Sudarshan, R. D. and Falck, J. R. (2010) Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. Front. Physiol. 1, 157 CrossRef PubMed
22. Seubert, J. M., Zeldin, D. C., Nithipatikom, K. and Gross, G. (2007) Role of epoxyeicosatrienoic acids protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 82, 50-59 CrossRef PubMed
23. Sodhi, K., Inoue, K., Gotlinger, K. H., Canestraro, M., Vanella, L., Kim, D. H., Manthati, V. L., Koduru, S. R., Falck, J. R., Schwartzman, M. L. and Abraham, N. G. (2009) Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J. Pharmacol. Exp. Ther. 331, 906-916 CrossRef PubMed
24. Mills, P. A., Huetteman, D. A., Brockway, B. P., Zwiers, L. M., Gelsema, A. J., Schwartz, R. S. and Kramer, K. (2000) A new method for measurement of blood pressure, heart rate, and activity in the mouse by radiotelemetry. J. Appl. Physiol. 88, 1537-1544 PubMed
25. Bukhari, I. A., Gauthier, K. M., Jagadeesh, S. G., Sangras, B., Falck, J. R. and Campbell, W. B. (2011) 14,15-Dihydroxyeicosa- 5(Z)-enoic acid selectively inhibits 14,15-epoxyeicosatrienoic acid-induced relaxations in bovine coronary arteries. J. Pharmacol. Exp. Ther. 336, 47-55 CrossRef PubMed
26. Pavlov, T. S., Levchenko, V., Karpushev, A. V., Vandewalle, A. and Staruschenko, A. (2009) Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel. Mol. Pharmacol. 76, 1333-1340 CrossRef PubMed
27. Levchenko, V., Zheleznova, N. N., Pavlov, T. S., Vandewalle, A., Wilson, P. D. and Staruschenko, A. (2010) EGF and its related growth factors mediate sodium transport in mpkCCDc14 cells via ErbB2 (neu/HER-2) receptor. J. Cell Physiol. 223, 252-259 PubMed
28. Pavlov, T. S., Ilatovskaya, D. V., Levchenko, V., Mattson, D. L., Roman, R. J. and Staruschenko, A. (2011) Effects of cytochrome P-450 metabolites of arachidonic acid on the epithelial sodium channel (ENaC). Am. J. Physiol. Renal Physiol. 301, F672-F681 CrossRef PubMed
29. Khan, M. A., Liu, J., Kumar, G., Skapek, S. X., Falck, J. R. and Imig, J. D. (2013) Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J. 27, 2946-2956 CrossRef PubMed
30. Hye Khan, M. A., Neckár, J., Manthati, V., Errabelli, R., Pavlov, T. S., Staruschenko, A., Falck, J. R. and Imig, J. D. (2013) Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. Hypertension 62, 905-913 CrossRef PubMed
31. Fyhrquist, F. I., Metsärinne, K. and Tikkanen, I. (1995) Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J. Hum. Hypertens. 5, S19-S24
32. Imig, J. D. (2000) Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. Am. J. Hypertens. 13, 810-818 CrossRef PubMed
33. Wang, D., Luo, Z., Wang, X., Jose, P. A., Falck, J. R., Welch, W. J., Aslam, S., Teerlink, T. and Wilcox, C. S. (2010) Impaired endothelial function and microvascular asymmetrical dimethylarginine in angiotensin II-infused rats: effects of tempol. Hypertension 56, 950-955 CrossRef PubMed
34. Schäfer, S. C., Pellegrin, M., Wyss, C., Aubert, J. F., Nussberger, J., Hayoz, D., Lehr, H. A. and Mazzolai, L. (2012) Intravital microscopy reveals endothelial dysfunction in resistance arterioles in angiotensin II-induced hypertension. Hypertens. Res. 35, 855-861 CrossRef PubMed
35. Modena, M. G., Bonetti, L., Coppi, F., Bursi, F. and Rossi, R. (2002) Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J. Am. Coll. Cardiol. 40, 505-510 CrossRef PubMed
36. Perticone, F., Ceravolo, R., Pujia, A., Ventura, G., Iacopino, S., Scozzafava, A., Ferraro, A., Chello, M., Mastroroberto, P., Verdecchia, P. and Schillaci, G. (2001) Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104, 191-196 CrossRef PubMed
37. Taddei, S., Versari, D., Cipriano, A., Ghiadoni, L., Galetta, F., Franzoni, F., Magagna, A., Virdis, A. and Salvetti, A. (2006) Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J. Am. Coll. Cardiol. 48, 508-515 CrossRef PubMed
38. Gao, J., Bellien, J., Gomez, E., Henry, J. P., Dautreaux, B., Bounoure, F., Skiba, M., Thuillez, C. and Richard, V. (2011) Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension. J. Hypertens. 29, 1128-1135 CrossRef PubMed
39. Imig, J. D., Zhao, X., Falck, J. R., Wei, S. and Capdevila, J. H. (2001) Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonamide analog of 11,12-epoxyeicosatrienoic acid. J. Hypertens. 19, 983-992 CrossRef PubMed
40. Hercule, H. C., Schunck, W. H., Gross, V., Seringer, J., Leung, F. P., Weldon, S. M., da Costa Goncalves, A. C. H., Huang, Y., Luft, F. C. and Gollasch, M. (2009) Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler. Thromb. Vasc. Biol. 29, 54-60 CrossRef PubMed
41. Zhao, D., Seth, D. M. and Navar, L. G. (2009) Enhanced distal nephron sodium reabsorption in chronic angiotensin II-infused mice. Hypertension 54, 120-126 CrossRef PubMed
42. Ortiz, R. M., Graciano, M. L., Seth, D., Awayda, M. S. and Navar, L. G. (2007) Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension. Am. J. Physiol. Renal Physiol. 293, F139-F147 CrossRef PubMed
43. Cowley, Jr, A. W. and Roman, R. J. (1996) The role of the kidney in hypertension. JAMA 275, 1581-1589 CrossRef PubMed
44. Beutler, K. T., Masilamani, S., Turban, S., Nielsen, J., Brooks, H. L., Ageloff, S., Fenton, R. A., Packer, R. K. and Knepper, M. A. (2003) Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension 41, 1143-1150 CrossRef PubMed
45. Gonzalez, A. A., Liu, L., Lara, L. S., Seth, D. M., Navar, L. G. and Prieto, M. C. (2011) Angiotensin II stimulates renin in inner medullary collecting duct cells via protein kinase C and independent of epithelial sodium channel and mineralocorticoid receptor activity. Hypertension 57, 594-599 CrossRef PubMed
46. Nakagawa, K., Holla, V. R., Wei, Y., Wang, W. H., Gatica, A., Wei, S., Mei, S., Miller, C. M., Cha, D. R., Price, Jr, E. et al. (2006) Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J. Clin. Invest. 116, 1696-1702 CrossRef
47. Hamm, L. L., Feng, Z. and Hering-Smith, K. S. (2010) Regulation of sodium transport by ENaC in the kidney. Curr. Opin. Nephrol. Hypertens. 19, 98-105 CrossRef PubMed
48. Wei, Y., Lin, D. H., Kemp, R., Yaddanapudim, G. S., Nasjletti, A., Falck, J. R. and Wang, W. H. (2004) Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol. 124, 719-727 CrossRef PubMed
49. Pidkovka, N., Rao, R., Mei, S., Gong, Y., Harris, R. C., Wang, W. H. and Capdevila, J. H. (2013) Epoxyeicosatrienoic acids (EETs) regulate epithelial sodium channel activity by extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated phosphorylation. J. Biol. Chem. 288, 5223-5231 CrossRef PubMed
50. May, A., Puoti, A., Gaeggeler, H. P., Horisberger, J. D. and Rossier, B. C. (1997) Early effect of aldosterone on the rate of synthesis of the epithelial sodium channel alpha subunit in A6 renal cells. J. Am. Soc. Nephrol. 8, 1813-1822 PubMed
51. Capdevila, J. and Wang, W. (2013) Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr. Opin. Nephrol. Hypertens. 22, 163-169 CrossRef PubMed